NERLYNX™ (neratinib) tablets for HER2+ Breast Cancer in the Extended Adjuvant Setting

FLINT, Mich., July 20, 2017

The most common adverse reactions associated with NERLYNX (≥5%) were diarrhea, nausea, abdominal pain, fatigue, vomiting, rash, stomatitis, decreased appetite, muscle spasms, dyspepsia, AST or ALT increase, nail disorder, dry skin, abdominal distention, epistaxis, weight decreased and urinary tract infection. 

Please click for Full Prescribing Information, including Patient Information. For additional IMPORTANT SAFETY INFORMATION, visit www.NERLYNX.com.

"Diplomat recognizes the importance of having an oncology team of pharmacists, nurses, and care coordinators who work hard every day to help our patients in need," said Paul Urick, Diplomat president. "With neratinib, we can offer new hope for patients coping with metastatic breast cancer."

To learn more about Diplomat's oncology program, visit diplomat.is/areas-of-excellence/oncology. 

Forward-Looking Statements
This press release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements give current expectations or forecasts of future events or our future financial or operating performance. The forward-looking statements contained in this press release are based on management's good-faith belief and reasonable judgment based on current information. These statements are qualified by important risks and uncertainties, many of which are beyond our control, that could cause our actual results to differ materially from those forecasted or indicated by such forward-looking statements. For a discussion of such risks and uncertainties, you should review Diplomat's filings with the Securities and Exchange Commission, including "Risk Factors" in Diplomat's Annual Report on Form 10-K for the year ended Dec. 31, 2016, and in subsequent reports filed with or furnished to the Securities and Exchange Commission. Except as may be required by any applicable laws, Diplomat assumes no obligation to publicly update such forward-looking statements, which are made as of the date hereof or the earlier date specified herein, whether as a result of new information, future developments or otherwise.